Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Bupivacaine in Lower Extremity Amputation
NCT04360421Phase 4Terminated
- Sponsor
- Loma Linda University
- Start
- Apr 2020
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bupivacaine in postoperative pain, sponsored by Loma Linda University. Primary endpoints: Total opioid use up to 4 weeks and Total cost of stay up to 4 weeks. Started Apr 2020; status: terminated.
02
Drugs
bupivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT04360421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04360421.